Dr. Karoly Nikolich

Dr. Karoly Nikolich

Chief Executive Officer at Alkahest, United States

Biography

Karoly Nikolich, PhD, is CEO of Alkahest, a Grifols company. He led Genentech’s entry into neuroscience during the 1980s and led and participated in the development of numerous protein therapeutics. He was Vice President of Research and Development at Lynx Therapeutics, a company that pioneered massively parallel nucleotide sequencing. He also served as Executive Director of the Stanford Neuroscience Institute in 2005-2007.
Karoly was also co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, including Neuropore, Angiochem, Hummingbird, Pascal, as well as several investment funds.
Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Adjunct Professor in the Department of Psychiatry at Stanford University Medical School.